Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

113 results about "Brain cancers" patented technology

The most common cancers that spread to the brain are those arising from cancers that originate in the lung, breast, and kidney as well as malignant melanoma, a skin cancer. The cells spread to the brain from another tumor in a process called metastasis.

Compositions and methods for derepressing RE1 silencing transcription factor target genes

The invention relates to compounds, compositions, and methods for derepressing RE1 silencing transcription factor (REST) target genes are provided. In particular, a peptide having the sequence TEDLEPPEPPLPKEN (SEQ. ID NO: 1) and EDLEPPEPPLPK (SEQ. ID NO: 15), or the reversed sequences made of D-amino acids (retro inverted, RI) nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. The peptides are useful to treat, prevent, or ameliorate conditions such as traumatic brain injury, epilepsy, dementia, Huntington's Disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer; diabetes, and peripheral nerve injury.
Owner:ALCAMENA STEM CELL THERAPEUTICS LLC

Methods for culturing primary cancer cells in brain organoids

Disclosed herein are methods of producing organoids. In some aspects, the methods involve producing organoids by implanting primary cancer cells such as glioblastoma cells into brain organoids, thereby producing brain cancer organoids. The method can comprise an incubation step in which the brain organoid is incubated with primary cancer cells in a hanging liquid droplet to produce the brain cancer organoid. In some aspects, the brain cancer organoids provide tools for understanding and treating cancers of the nervous system, such as glioblastoma.
Owner:RGT UNIV OF CALIFORNIA

Anti-gal3 antibodies and methods of use

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Owner:TRUEBINDING INC

Quinazoline derivative salt crystal form, preparation method and application

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.
Owner:WEISHANG (SHANGHAI) BIO PHARMA CO LTD

Methods and compositions for enhancing radiation therapy with dopamine receptor (DRD2)‑binding compounds

PCT designated stageWO2026176390A1CariprazinePhenylpiperazine
Provided are methods and compositions for enhancing radiotherapy in various cancers by administering dopamine receptor (DRD2)‐binding phenylpiperazine derivatives such as brexpiprazole, cariprazine, pipamperone, and perospirone. In vitro studies show that combining these agents with ionizing radiation (e.g., 5 Gy) significantly reduces cancer cell survival, suppresses metastatic and stemness markers (e.g., CD44, MMP‑2, Snail, Nanog), and promotes apoptosis. Fractionated or single‐fraction radiation regimens can be paired with DRD2 antagonists to lower treatment‐resistant phenotypes, decrease the likelihood of recurrence, and potentially reduce necessary radiation dosages. The approach applies to breast, prostate, lung, pancreatic, and brain cancers, among others. Depending on tumor characteristics, additional chemotherapeutic or immunotherapeutic agents may further improve outcomes.
Owner:VSPHARM TECH CO LTD

An antitumor macrolide polymer and a preparation method and application thereof

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.
Owner:OCEAN UNIV OF CHINA

FBXO21 MEDIATED P85a UBIQUITYLATION AS A THERAPEUTIC TARGET IN CANCER

PCT designated stageWO2026072967A1Organic chemistryAntineoplastic agentsGastrointestinal cancerChronic myeloproliferative disorders
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:UNIV OF UTAH RES FOUND +1

Compositions and methods for inhibiting carp-1 binding to nemo

PendingUS20250257058A1Organic chemistryAntineoplastic agentsGastrointestinal cancerChronic myeloproliferative disorders
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1

4'-Thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

ActiveCN112513061BOrganic active ingredientsSugar derivativesGastrointestinal cancerChronic myeloproliferative disorders
The present disclosure relates to 4'-thio-nucleotides and nucleoside compounds for the treatment of various cancers, such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative tumors and plasma cell neoplasms (myeloma). The abstract is intended to be a scanning tool for the purpose of searching in a specific field and is not intended to limit the present invention.
Owner:SOUTHERN RESEARCH INSTITUTE

Cathepsin Z Specific Monoclonal Antibody and Use thereof

The present invention relates to a monoclonal antibody that specifically binds to cathepsin Z and its uses. The monoclonal antibody of the present invention that specifically binds to cathepsin Z, or its antigen-binding fragment, can inhibit the in vivo tumor formation of CtsZ-overexpressing cancers, specifically brain cancers, and more specifically mesenchymal brain cancer stem cells by specifically binding to CtsZ. Accordingly, it can be usefully utilized for the treatment of patients with CtsZ-overexpressing cancers, preferably patients with mesenchymal brain cancers, and more preferably patients with glioblastoma. Furthermore, the monoclonal antibody of the present invention, or its antigen-binding fragment, can enable the diagnosis of CtsZ-overexpressing cancers, specifically brain cancers, and more specifically glioblastoma by specifically binding to cathepsin Z.
Owner:NBIOS INC +1

Crystal form of substituted 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-C] quinoline-2-ketone derivative, crystal form of salt of substituted 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-C] quinoline-2-ketone derivative, preparation method and application

PendingCN118984706ALow efflux rateDecreased efflux rateOrganic active ingredientsOrganic chemistry methodsDiseasePipequaline
The invention provides a free alkali crystal form and a salt crystal form of a substituted 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-c] quinoline-2-ketone derivative (shown in a formula (I)) as well as a preparation method and application of the free alkali crystal form and the salt crystal form, and particularly relates to the free alkali crystal form and the fumarate crystal form of the 1-(3, 3-difluoropiperidine-4-yl)-imidazo [4, 5-c] quinoline-2-ketone derivative shown in the formula (I). The free alkali crystal form and the salt crystal form provided by the invention are good in stability, can be used for treating diseases such as cancers, cancers accompanied by central nervous system metastasis, meningeal metastasis, primary brain cancer or glioma (especially combined treatment with a DNA double-strand breakage inducer), have good bioavailability and half-life period, and can be used for preparing a medicine for treating the diseases such as the cancers, the cancers accompanied by central nervous system metastasis, meningeal metastasis, primary brain cancer or glioma and the like. The method is of great significance to further research on the curative effect of the solid preparation. # imgabs0 #
Owner:钟卫

Riluzole prodrugs and their use

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
Owner:BIOHAVEN THERAPEUTICS LTD

Linezolid derivatives and applications thereof

PCT designated stageWO2025217291A1Heterocyclic compound active ingredientsLinezolidBrain cancers
The present disclosure relates to linezolid derivatives, in particular of Formula (I), the definition of p, A, A1 and R1 are as defined in the specification; the process of preparing the same and uses thereof in treatment of brain cancers, in particular glioblastoma.
Owner:TAIPEI MEDICAL UNIV +1

Humanized Anti-ca ix antibodies and methods of their use

The present invention relates to a humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.
Owner:MABPRO AS

Local targeting photodynamic therapy device for treating cancer and control method thereof

The present invention relates to a local targeting photodynamic therapy device for treating cancer. In more detail, an endoscope is disposed at the center of the end of a probe for photodynamic therapy, and a plurality of optical fibers are disposed along the edge to irradiate a plurality of lights to a lesion site, wherein the plurality of optical fibers of the probe receive light from independent light sources to independently perform light irradiation. The present invention is a device for minimizing damage to unnecessary normal tissue by adjusting the light irradiation area, i.e., each independent light source determines a light irradiation area including a lesion site in a real-time image provided by an endoscope disposed at the end of the probe, and only causes the independent light source that irradiates the determined light irradiation area to emit light, thereby achieving local light irradiation, etc. The local targeting photodynamic therapy device of the present invention can treat a variety of cancers or tumors, including cervical cancer, female cancers (endometrial cancer, ovarian cancer, breast cancer), skin cancer, brain cancer, etc., which are small and can be treated locally.
Owner:AMOS PHARM CO LTD

2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)-1-(piperidin-1-yl)ethan-1-one etodolac derivative as eukaryotic elongation factor 2 kinase (EEF2K) inhibitor for targeted cancer therapy

PendingUS20260015359A1Organic chemistryAntineoplastic agentsDiseaseEukaryotic Elongation Factor-2 Kinase
A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.
Owner:BAHCESEHIR UNIVERSITY

Application of bangia fusco-purpurea coumarin compound or structural analogue of bangia fusco-purpurea coumarin compound in preparation of anti-brain cancer drugs or reagents

The invention relates to application of a bangia coumarin compound or a structural analogue of the bangia coumarin compound in preparation of an anti-brain cancer drug or reagent. The bangia coumarin compound is hesperel enol which is a bangia coumarin compound. And the structural analogue of the coumarin compound is a structural analogue hesperelactone hydrate of the coumarin compound hesperelactone of bangia fusco-purpurea. The compound can reduce the survival rate of brain cancer cells, reduce invasion of the brain cancer cells and inhibit the characteristics of brain cancer tumor stem cells, so that the compound can be used for preparing drugs or reagents for treating brain cancer. Meanwhile, the lowest concentration of the hesperidin hydrate for inhibiting the tumor stem cell characteristics of brain cancer is the same as that of a clinical medicine temozolomide, and the lowest concentration of the hesperenol is lower than that of the temozolomide. In addition, the anti-brain cancer effect of the nerolidinol further comprises the effect of inhibiting a brain cancer tumor stem cell marker.
Owner:JIMEI UNIV

Methods and materials for assessing and treating cancer

This document relates to methods and materials for assessing and / or treating mammals (e.g., humans) having brain cancer (e.g., glioblastoma (GBM)). For example, the presence of a population of CD9+ extracellular vesicles (EVs; e.g., CD9+ plasma EVs) having a distinct profile in a sample (e.g., a blood sample) obtained from a mammal (e.g., a human) can be used to identify that mammal as having brain cancer (e.g., GBM). Also provided are materials and methods for treating mammals (e.g., a human) having brain cancer (e.g., GBM)
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Purine covalent based CDK12 inhibitors

Disclosed are purine derivatives of formulae (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods involving the inventive compounds or compositions for treating and / or preventing cell proliferative diseases including certain cancers of breast, brain, ovarian, lung, colorectal cancer, leukemias, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma and inflammatory and myotonic dystrophy type 1 diseases in a mammal. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of kinases, such as a cyclin-dependent kinases (CDK) (e.g., CDK12 / 13), and therefore, induce potent antiproliferative and apoptotic effects and / or inhibit transcription in the subject.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Organic compositions to treat KRAS-related diseases

The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.
Owner:ARROWHEAD PHARMACEUTICALS INC

Boosting osmotic blood-organ barrier opening for improved delivery of therapeutics to organs

Osmotic blood-tissue barrier opening offers a promising approach to surmounting challenges posed by the blood-brain barrier in the treatment of brain cancer and neurological diseases. By enhancing permeability of any blood-organ barrier, enabling precise targeting, reducing toxicity, being less invasive, and potentially accommodating larger therapeutic molecules, osmotic blood-organ barrier opening represents a valuable strategy in the fight against diseases such as brain cancer and neurological diseases.
Owner:UNIV OF MARYLAND

Prodrugs of riluzole and their method of use

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
Owner:BIOHAVEN THERAPEUTICS LTD

Macrolide-NOX4 conjugates and uses thereof

The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis), acute respiratory distress syndrome (ARDS) or for treating cancer (e.g., a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +6

Anti-gal3 antibodies and methods of use

To provide anti-Gal3 antibodies and methods of use.SOLUTION: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Gal3 and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of antibodies or binding fragments thereof for treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.SELECTED DRAWING: Figure 1
Owner:TRUEBINDING INC

Compositions and methods for derepressing RE1 silencing transcription factor target genes

PendingAU2020386637B2Huntingtons choreaBrain cancers
The invention relates to compounds, compositions, and methods for derepressing RE1 silencing transcription factor (REST) target genes are provided. In particular, a peptide having the sequence TEDLEPPEPPLPKEN (SEQ. ID NO: 1) and EDLEPPEPPLPK (SEQ. ID NO: 15), or the reversed sequences made of D-amino acids (retro inverted, RI) nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. The peptides are useful to treat, prevent, or ameliorate conditions such as traumatic brain injury, epilepsy, dementia, Huntington's Disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer; diabetes, and peripheral nerve injury
Owner:ALCAMENA STEM CELL THERAPEUTICS LLC

Small molecule modulators of SIRT5 and uses thereof

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of carbothioamide (and structurally related) small-molecule compounds which function as inhibitors of SIRT5, and their use as therapeutics for the treatment of diseases associated with posttranslational modification functions (e.g., diseases associated with SIRT5 activity) (e.g., cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), ovarian cancer, colorectal cancer (CRC), acute myeloid leukemia (AML), Ewing's sarcoma, brain cancer, pancreatic cancer, renal cancer, breast cancer, prostate cancer, lung cancer, leukemia and lymphoma), diabetes, autoimmune diseases, inflammatory diseases, fibrotic diseases, cardiovascular diseases, and neurodegenerative diseases).
Owner:THE RGT UNIV OF MICHIGAN

Combination Therapy for Brain Cancer

PendingUS20260151423A1Solution deliveryPharmaceutical non-active ingredientsDuvelisibPanobinostat
Combination therapies for use in the treatment of brain tumours, particularly glioma and embryonal brain tumours. Disclosed herein are pharmaceutical compositions comprising a complex of Panobinostat and a cyclodextrin, a second pharmaceutical agent, and a pharmaceutically acceptable excipient, diluent or carrier, in which the second pharmaceutical agent is Niclosamide, Dasatinib or Duvelisib. Associated methods of treatment and use are further disclosed.
Owner:BIODEXA LTD